Veeva Systems Inc. (NYSE: VEEV) — The Regulated Monopoly Thrown Out With the SaaS Bathwater

Independent equity research. Report date: 2026-06-19. Fiscal year ends January 31; “FY2026” = year ended Jan 31, 2026.

⚡ Claude’s Take

This is the author’s own independent opinion and general information, not investment advice. The analysis that follows takes no position and carries no price target — it discusses valuation only as embedded expectations and scenarios.

Verdict: BUY / accumulate-on-weakness — a quality compounder at a trough-of-its-own-history multiple, on a binary CRM catalyst. Medium conviction. Constructive entry zone ~$130–160 (≈18–22x net-cash-adjusted forward EPS / ≈5–6x EV/sales), leaning harder toward the low-$130s/high-$120s, where the AI- and Salesforce-fear discount more than pays you for the risk that the Commercial-CRM franchise is permanently impaired.

The market is pricing Veeva as though its slower, Salesforce-contested CRM business (~45% of revenue) is the company. It isn’t. The other ~55% — the Vault-native R&D, Regulatory, Quality and Safety stack — is a near-monopoly in validated, mission-critical life-sciences workflows that is still compounding ~20%, is structurally far harder for AI to disintermediate (document- and compliance-centric, not seat-centric), and owns the proprietary data layer that any credible AI competitor would have to source from Veeva anyway. A 16%-growing, 45%-non-GAAP-operating-margin, ~44%-FCF-margin, net-cash, regulated-workflow monopoly with >100% returns on operating capital now changes hands at ~5.8x EV/revenue, ~13x EV/FCF, and a ~7.6% EV/FCF yield — its cheapest valuation in its entire public history (AZI puts P/E, P/S and P/B all at the 2nd percentile of the last decade). The embedded expectation is ~3–5% perpetual FCF growth; the business is doing ~16%. That gap is the opportunity.

I temper this to accumulate-on-weakness rather than table-pounding for three honest reasons: (1) the tape is a falling knife that has not stabilized — down ~46% in twelve months, ~1% off its 52-week low, no momentum turn, so a value buyer here is early; (2) the bear case is real and binary — the top-20-pharma CRM scorecard genuinely deteriorated (management’s own “18 of 20 → 14 of 20 → 10 Veeva / 6 Salesforce / 4 undecided”), and “cheap vs its own bubble” is a low bar that can stay low; and (3) capital allocation just revealed a blemish — a first-ever buyback that bought ~$180M at $224 (now deeply underwater) and an executive-comp plan with no financial performance metric at all. Framing: contrarian-value / quality-at-a-trough-multiple, not momentum. Net cash (~$39/share), 44% margins, and the 7.6% FCF yield floor the downside to roughly dead-money, not ruin; the upside requires only that the AI/Salesforce fear proves overdone — which the +20% R&D/Quality majority is already quietly disproving. Flips bullish (high conviction) on one to two quarters of a stabilizing-to-improving Commercial-CRM win/loss scorecard plus evidence Veeva AI/Falcon monetizes as consumption-additive. Flips bearish on the CRM scorecard deteriorating further (Salesforce winning the majority of top-20 re-platforming decisions) or R&D/Quality growth decelerating below ~15%, which would prove the disruption is system-wide, not CRM-contained. Tag: the regulated monopoly thrown out with the SaaS bathwater.

📈 Stock Price Action — Five-Year Event Map

VEEV is a full-cycle round trip and then a second, sharper break. Over five years it ran from the mid-$200s to a $341 all-time high (Aug-2021), gave most of it back in the 2022 rate shock, clawed almost all the way back to a $306 52-week high (Oct-7-2025) — within ~10% of the bubble peak — and then crashed ~52% to a $151 52-week low (Apr-10-2026), closing at $153.30 on Jun-18-2026. It sits ~55% below its peak (rs_peak −55%), ~25% below its falling 200-day EMA (~$202), down ~46% over the trailing twelve months, and roughly 1% above its 52-week low — i.e. near the bottom of its own five-year range with no confirmed momentum turn. (Price moves are FACT, from the AZI price series; attributed drivers are INTERPRETATION.)

Cycle narrative. (1–2) Veeva participated fully in the 2021 SaaS bubble and its 2022 unwind — both macro, not idiosyncratic. (3) The 2023–2025 recovery was earned: the Vault R&D/Quality engine re-accelerated and operating margins expanded materially, carrying the stock back to within striking distance of its old high. (4) The break is precisely datable: on the November 20, 2025 fiscal-Q3 call, management — which had guided investors to expect it would retain ~18 of the 20 largest pharma commercial-CRM accounts as they re-platform off Salesforce onto Veeva’s own Vault CRM — cut that to “14 or so,” conceding ~6 of the top 20 are leaning to Salesforce/other; the stock fell ~9.8% the next session despite a Q3 beat and a raised full-year guide. (5) That single disclosure detonated a broader, months-long de-rate as the market fused it with the 2026 “AI kills application SaaS” narrative crushing the whole busted-SaaS cohort (DOCU, HUBS, PCOR — Veeva’s factor-neighbors). (6) The May-2026 Falcon AI launch and a clean Q1 FY27 beat produced only a brief failed bounce to ~$183 before the stock rolled back to $153 — the signature of a multiple problem, not an earnings problem.

1. Executive Summary

Veeva Systems is the dominant vertical-software franchise for the global life-sciences industry — pharmaceutical, biotech, and increasingly medtech and consumer-health companies. It sells cloud applications for two broad domains: Commercial (CRM for field sales, plus PromoMats content, OpenData/Crossix/Compass data and analytics) and R&D & Quality (the Vault platform spanning clinical trial management, regulatory submissions (RIM), quality/QMS, and pharmacovigilance/safety). FY2026 (ended Jan-31-2026) revenue was $3,195M, +16.3%, of which 84% is subscription and ~95% is effectively recurring; gross margin is 75.5%, GAAP operating margin 28.7%, non-GAAP operating margin ~44.9%, and free cash flow $1,415M (a ~44% FCF margin). The balance sheet holds ~$6.5B of cash and investments against essentially zero debt.

The business is a genuine, financially-validated moat — not a marketing claim. In Greenwald’s taxonomy it combines demand-side customer captivity (ripping out an FDA-validated clinical, regulatory, safety, or quality system mid-lifecycle carries regulatory risk and re-validation cost that swamp any price saving from a rival), economies of scale within a deliberately narrow vertical (one R&D organization — ~24% of revenue, roughly 2x sales & marketing — amortized across essentially the entire industry), and a proprietary-data intangible (OpenData reference data, Crossix patient/claims analytics). The financial fingerprint is unambiguous: gross margin rising with scale, operating margin up from 18% (FY24 trough) to 29%, ROE ~23%, and — once the idle $6.5B cash hoard is stripped from the denominator — a return on operating capital above 100%, on negative tangible invested capital, because deferred-revenue float funds the business.

So why has the stock halved? Two forces, one company-specific and one sector-wide. Company-specific: Veeva’s legacy CRM was built on Salesforce’s platform; the OEM agreement expired September 1, 2025 (winding down through 2030), and Veeva is migrating its base onto its own Vault CRM. On the November-2025 earnings call management conceded the top-20-pharma retention scorecard had slipped from a previously-implied “18 of 20” toward “14 of 20” — i.e. Salesforce, now armed with IQVIA’s licensed CRM IP, is a live competitor for ~45% of Veeva’s revenue. Sector-wide: the 2026 market is re-rating application SaaS downward on the thesis that AI agents compress per-seat software demand; Veeva’s factor-neighbors (DocuSign, HubSpot, Procore) have been hit hard. The combination took VEEV from ~$306 (Oct-2025) to ~$151 (Apr-2026) and to the 2nd percentile of its own ten-year valuation range on P/E, P/S, and P/B.

The central analytical tension: the de-rate has extrapolated a ~45%-of-revenue CRM problem onto a company whose ~55% majority — the Vault R&D/Quality stack — is accelerating (~20%+), is document/compliance-centric and far less exposed to a seat-destroying AI model, and is essentially unchallenged. At ~$18.7B EV the market prices ~3–5% perpetual FCF growth against ~16% delivered growth. The downside is floored (net cash, 44% margins, 7.6% FCF yield ≈ dead money); the upside requires only that the fear be overdone. The risks are equally real and binary: if Salesforce wins the majority of top-20 re-platforming decisions, or AI proves seat-destructive across both segments, “cheap” becomes a value trap. Capital allocation reveals a 25-year habit of hoarding idle cash, a first-ever buyback poorly timed into the high, and a compensation plan tied to no financial metric whatsoever — governance blemishes that temper, without negating, an elite operating record.

2. Business Overview

What Veeva does. Veeva sells cloud software and data to the life-sciences industry — a deliberately single-vertical strategy (“industry cloud”) that the company has pursued since its 2007 founding. Its customers are pharmaceutical and biotech manufacturers (from the largest global pharma to thousands of emerging biotechs), plus a growing footprint in medical devices, consumer health, chemicals, and cosmetics. The thread running through every product is that life-sciences processes are regulated — by the FDA, EMA, and equivalents worldwide — so the software must be validated, auditable, and compliant (GxP, 21 CFR Part 11). That regulatory overlay is the source of both the narrow addressable market and the deep moat.

Revenue model and segmentation. FY2026 revenue of $3,195.3M splits into subscription services $2,684.2M (84%) and professional services & other $511.1M (16%). Subscription is recurring, multi-year, and high-margin; professional services (implementation, configuration, managed services) is lower-margin and largely exists to drive and protect subscription adoption. Counting multi-year subscription plus recurring managed services, ~95% of revenue is effectively recurring.

Since FY2025 Veeva reports revenue in two solution areas rather than the older “Commercial Cloud / Development Cloud” labels:

The single most important fact most “Veeva = pharma CRM” mental models miss: the growth engine and the majority of revenue have decisively shifted to the Vault-native R&D/Quality stack. A decade ago Veeva was a CRM company with a data side-business; today CRM is roughly 20% of total revenue (down from ~25% two years ago, per management), and the faster-growing, less-contested Vault platform is the larger and more strategically defensible half of the company.

Customers and concentration. Veeva served ~1,552 customers at FY2026 year-end. Concentration is moderate and declining in risk terms: the top-10 customers were ~28% of revenue and no single customer exceeded 10%. The customer base spans the 20 largest global pharma (which use many Veeva products across both segments) down to single-product emerging biotechs. Geographically, revenue is ~60% North America, ~29% Europe, with the remainder Asia-Pacific and rest-of-world.

Public Benefit Corporation. In February 2021 Veeva became a Delaware Public Benefit Corporation — legally bound to balance stockholder interests with the interests of customers and society. In practice this has had limited operational effect beyond signaling a long-term, customer-first orientation; it did, however, coincide with the elimination of the dual-class share structure.

Verdict. A high-quality, overwhelmingly-recurring, single-vertical software and data franchise whose center of gravity has shifted from the contested CRM origin toward a dominant, faster-growing, regulated R&D/Quality platform. The business model — multi-year subscriptions, deferred-revenue float, asset-light delivery — is among the best structures in software.

3. Industry Dynamics

Market structure and size. Veeva operates in life-sciences-specific software and data — a niche within the broader enterprise-software market, but a deep and growing one. Global pharma/biotech R&D spending runs into the hundreds of billions annually; commercial (sales & marketing) spend is similarly large; and the digitization of clinical trials, regulatory submissions, quality systems, safety, and commercial engagement is a multi-decade secular tailwind. Veeva’s own stated long-term ambition (a “$20B+ revenue by 2030+” aspiration management has floated) implies it believes its serviceable market is multiples of its current ~$3.2B revenue. The key structural feature is not raw size but defensibility: the addressable market is narrow enough, and the compliance/validation requirements specialized enough, that horizontal generalists rationally under-invest in it.

Why the vertical is structurally attractive (for the incumbent). Life-sciences software competition collapses, workflow by workflow, to a handful of names — and often to Veeva plus one legacy alternative. The reasons are durable:

• Regulatory validation as a barrier. Systems that touch GxP processes (clinical, regulatory, safety, quality) must be validated and audit-ready; switching mid-lifecycle risks regulatory findings and requires costly re-validation. This is a demand-side barrier created by the customer’s own risk function, not by Veeva.
• Fragmented, retreating legacy competition. The pre-Veeva landscape was per-module legacy software (Oracle Siebel/Argus, OpenText, Documentum, Medidata) and in-house builds. Much of it is being actively retired. Most strikingly, IQVIA exited standalone life-sciences CRM by licensing its CRM IP to Salesforce rather than continuing to build — a supply-side withdrawal that, in Marathon capital-cycle terms, is favorable for the remaining disciplined incumbent.
• Scale economics within a narrow vertical. Because Veeva amortizes one large R&D organization (~$767M, ~24% of revenue) across essentially the whole industry, a generalist would have to fund comparable compliance-specific R&D for a fraction of the revenue — a losing proposition. That is why R&D runs ~2x sales & marketing at Veeva: the product, once validated and embedded, largely sells itself into a captive base.

Marathon capital-cycle read. The supply side is disciplined and, in CRM specifically, consolidating around Salesforce-vs-Veeva rather than fragmenting. The prize per individual workflow is too small to attract well-capitalized new generalist entrants, and legacy incumbents are withdrawing. The one genuine capital-cycle disruptor is agentic AI, which could either (a) expand Veeva’s wallet share (automating clinical-document, safety-case, and regulatory work it can charge for — the Falcon thesis) or (b) compress the seat-based economics of the Commercial/CRM layer. This is the live uncertainty.

The structural risk: single end-market. The flip side of vertical focus is concentration. A sustained downturn in pharma/biotech R&D funding (biotech capital-markets freeze, IRA drug-pricing pressure compressing pharma margins and project counts, large-pharma M&A reducing the customer count) hits Veeva’s entire book at once, not one segment. The emerging-biotech funding environment in particular is a swing factor for new-logo growth.

Verdict. Structurally good for the incumbent leader: a narrow, regulated, high-switching-cost niche where competition is concentrated and partly retreating, scale economics favor the largest player, and the secular digitization tailwind is long. The two genuine threats are end-market cyclicality (single vertical) and the AI disruption of seat-based commercial software — neither of which changes the verdict that this is a better industry to lead than almost any horizontal software category.

4. Competitive Position

The moat, named. Veeva possesses a genuine, multi-stranded moat — and, crucially, one that surfaces in the financials (the no-fluff test). The mechanism, in Greenwald’s taxonomy:

1. Demand-side customer captivity (primary). For the regulated R&D/Quality workflows — clinical, regulatory submissions, quality, pharmacovigilance — the cost of switching is not merely re-implementation; it is re-validation of a system regulators have accepted, mid-flight on active trials and submissions, with the attendant compliance risk. The expected value of switching to a cheaper rival is frequently negative even before considering data migration. This captivity is why Vault renewals are near-universal and why the R&D/Quality segment compounds ~20% with minimal churn.
2. Economies of scale within a narrow vertical (reinforcing). One compliance-specific R&D engine amortized across the industry. No generalist can match Veeva’s life-sciences-specific feature depth at a rational cost, and no pure niche player can match its scale.
3. Proprietary-data intangible (reinforcing). OpenData (HCP/HCO reference data), Crossix (privacy-safe patient/claims analytics), Compass (de-identified longitudinal patient data), and Link create data assets that compound with usage and that competitors must source — often, ironically, from Veeva — to compete in commercial analytics. This is the closest Veeva comes to a network/data effect, though it is better described as a hard-to-replicate intangible than a true network effect.

The financial fingerprint that proves it. A moat that cannot be tied to a deteriorating financial outcome in its absence is not a moat. Veeva’s is: 75.5% gross margin, 28.7% GAAP / 44.9% non-GAAP operating margin, ~23% ROE, >100% return on operating capital, and — the tell — R&D at ~2x S&M, the spending profile of a company whose product sells itself into a captive installed base rather than one that must buy its growth. Market share in the core regulated Vault workflows is high and stable-to-rising (the Greenwald share-stability test passes for R&D/Quality).

The central durability test: Salesforce → Vault CRM. Here the moat is genuinely being stress-tested, and the test is the whole bear case. The facts, from the 10-K:

• Veeva’s legacy CRM was built on Salesforce’s platform under an OEM agreement. That agreement expired September 1, 2025. During a wind-down to September 1, 2030, Veeva cannot sell Salesforce-platform apps to new customers and is capped at 150% of existing seats; legacy Veeva CRM is supported through December 31, 2029.
• Veeva built and is migrating customers to its own Vault CRM (native to the same Vault platform as PromoMats, Medical, and the R&D/Quality stack). The strategic prize is full-stack control: no Salesforce royalty, better unit economics, and a single data fabric uniting commercial and R&D — deepening, SAP-style, the lock-in for customers who stay.
• But re-platforming is exactly the moment switching costs are temporarily lowered. A customer forced to re-implement its CRM can, at that moment, evaluate alternatives at lower incremental friction. And the credible alternative is now real: Salesforce Life Sciences Cloud, armed with IQVIA’s licensed CRM IP, plus Microsoft as a distant third.

The scorecard the market is watching, in management’s own words: a previously-implied “18 of the top 20” pharma commercial-CRM accounts retained, cut on the Nov-2025 call to “14 or so,” and described on the Q1 FY27 call (Jun-2026) as “10 wins for Veeva, 6 Salesforce, 4 undecided.” That is a real, material concession: Salesforce is winning a meaningful minority of the largest accounts’ re-platforming decisions.

How to weigh it. Three points keep this from being thesis-ending. First, the contested franchise is the slower-growing ~45% minority (CRM is ~20% of total revenue); the dominant, accelerating ~55% (R&D/Quality) is not in question and is far harder to dislodge. Second, even a rival CRM must source the HCP/patient data layer Veeva largely owns. Third, the AI seat-risk is concentrated in the same Commercial pillar — the R&D/Quality stack is document- and consumption-centric, not seat-elastic, and Veeva owns the data substrate reliable pharma AI depends on. The honest read: the migration more probably widens than breaks the overall moat, but it has clearly narrowed the Commercial-CRM moat from “uncontested” to “contested,” and the market is right to have repriced that segment — it has simply repriced the whole company as if the contest extended everywhere.

Direct competitor comparison. In R&D/Quality: legacy Oracle, Medidata/Dassault (clinical), OpenText/Documentum (content) — fragmented, per-module, and being displaced; Veeva is the share-gaining consolidator. In Commercial CRM: Salesforce Life Sciences Cloud (+ IQVIA IP) is the live threat; IQVIA itself exited standalone CRM. In data/analytics: IQVIA (the data incumbent) competes with Crossix/OpenData, but Veeva has won meaningful share by bundling data with workflow.

Verdict. A durable advantage, not a crowded market — anchored in regulatory switching costs, narrow-vertical scale economics, and proprietary data, and confirmed by elite, scale-improving economics. The Salesforce→Vault CRM re-platforming is the single most important durability test in the story; it has demonstrably contested the ~45% Commercial pillar (Salesforce is winning some top-20 accounts) without touching the dominant ~55% R&D/Quality core. The moat is intact where it matters most and narrowed where the market is now over-focused.

5. Growth History and Forward Opportunities

Historical growth — a decelerate-then-stabilize arc. Veeva grew ~25–30% in its earlier public years, decelerated into a +9.7% trough in FY2024 (a digestion year compounded by a biotech funding winter and a one-time data-product transition), then re-accelerated and stabilized at ~16%:

The composition under the headline matters more than the headline. The two pillars diverge sharply: Commercial Solutions grows low-teens (~11–14%) and is the Salesforce-contested franchise; R&D & Quality Solutions grows ~20%+ and is the Vault-native, near-uncontested engine. The blended ~16% is therefore a carry trade — the faster, more defensible majority carrying the slower, contested minority. The durability of the 16% depends on R&D/Quality holding ~20% while CRM does no worse than stabilize.

Forward opportunities (the bull’s growth runway):

• R&D/Quality penetration. Continued displacement of legacy Oracle/Medidata/OpenText/in-house systems across clinical, RIM, quality, and safety — the largest, most defensible runway, still well under-penetrated industry-wide.
• Vault CRM as a re-platforming opportunity, not only a risk. Every retained migration is also a chance to expand into adjacent Vault commercial modules on a unified data fabric, raising per-customer revenue for the ~14-of-20 (and the broad mid-market/biotech base) that stay.
• AI / Veeva Falcon. Launched at the May-2026 Veeva Summit, Falcon is an “agentic labor” platform that automates outsourced clinical-document, safety-case, and regulatory work, priced per-document/per-task (consumption, not seats). If it monetizes, it expands wallet share into services budgets Veeva does not today capture — and, critically, it is additive rather than seat-cannibalizing. The Ostro acquisition (AI engagement) adds commercial-AI capability. AI monetization is immaterial in FY2027 guidance — it is optionality, not yet a number.
• Data Cloud (Crossix/Compass/OpenData). A higher-growth, higher-margin data franchise that both competes with IQVIA and deepens commercial lock-in.
• Adjacent verticals. QualityOne/RegulatoryOne extend the Quality stack beyond pharma into chemicals, cosmetics, and consumer goods — a TAM extension.

Quality of growth. High. It is overwhelmingly organic (Veeva is famously build-not-buy), subscription-led, and land-and-expand within a captive base (net retention historically strong). The deceleration from 25–30% to 16% reflects the law of large numbers and the CRM contest, not a collapse in unit economics.

Verdict. High-quality but decelerated growth. The economics of the growth are excellent (organic, recurring, high-margin, capital-light); the pace has stepped down to ~16% and its durability rests on the R&D/Quality engine sustaining ~20% while CRM stabilizes. AI/Falcon and Data Cloud are credible accelerants but unproven in the numbers. This is the crux of the valuation debate: the market prices the deceleration as terminal; the bull case is that it is a plateau, not a slope.

6. Financial Quality

Revenue quality. Among the best in software: 84% subscription, ~95% recurring, multi-year contracts, deferred-revenue float, and CFO/net-income consistently 1.56–1.79x (cash-backed earnings, no accrual games). Deferred revenue grew +16.9% in FY2026 — in line with revenue, i.e. no pull-forward flattering the top line.

Margins and operating leverage. Economics improve unambiguously with scale. Gross margin rose from 72.8% (FY22) to 75.5% (FY26). GAAP operating margin expanded from an 18.2% trough (FY24) to 28.7% (FY26) and 30.9% in Q1 FY27. Non-GAAP operating margin is ~44.9%. Incremental margins exceed 50%. This is the signature of a business with high fixed-cost R&D and near-zero marginal delivery cost.

Quality-of-earnings fix #1 — returns on capital. The headline ~10.5% ROIC is misleading and understates the business quality. It is an artifact of burying the entire $6.56B cash/investments hoard in the capital base. Strip the idle cash: NOPAT (~$697M) on operating equity ex-cash (~$654M) ≈ 107%; on tangible operating capital the figure is effectively infinite, because Veeva operates on negative tangible invested capital (~−$256M) — deferred-revenue float funds the working capital. This is an elite asset-light franchise. The low headline ROIC is a verdict on lazy capital allocation of excess cash, not on the economics of the business.

Quality-of-earnings fix #2 — the GAAP/non-GAAP bridge is ~92% SBC. The ~16-point gap between 28.7% GAAP and ~44.9% non-GAAP operating margin is almost entirely stock-based compensation (plus ~8% intangible amortization). SBC is genuinely non-cash, so the adjustment is honest in form — but SBC is a real, dilutive economic cost. True owner economics sit nearer the GAAP 28.7% margin than the 44.9% non-GAAP figure. The mitigant: SBC is contained and falling as a share of revenue (16.7% peak FY24 → 14.8% FY26 → 13.5% Q1 FY27), and net dilution has been only +2.9% over four years (~0.7%/yr) — exceptionally shareholder-friendly for a growth-SaaS, and (until the FY26 buyback) entirely unoffset by repurchases.

Cash flow and balance sheet. FCF of $1,415M at a ~44% margin, near-zero capex (asset-light), zero financial debt (only ~$96M of finance leases), and ~$6.5B of cash and short-term investments — ~$39/share of net cash, ~26% of the $153 share price. Valuation must be done on EV, not market cap. A caveat for forward modeling: ~9% of pretax income is rate-sensitive interest income on the cash pile, and the FY23–24 GAAP EPS was flattered by sub-teen tax rates (4–11%); the tax rate has normalized to ~24%, which should be used forward.

Verdict. Economics unambiguously improve with scale — rising gross and operating margins, 50%+ incremental margins, ~44% FCF margin, >100% return on operating capital, near-zero capital intensity, contained and falling dilution, and no accounting red flags. This is a high-quality compounder. The only blemishes are the lazy $6.5B balance sheet (a returns drag, not an economics flaw) and the fact that true owner margins are the high-20s GAAP, not the mid-40s non-GAAP. The genuine open question is not quality but growth durability.

7. Capital Allocation

Philosophy: superb operator, lazy treasurer, late-and-clumsy capital-returner. Veeva’s capital allocation is a study in contrasts. On the operating side it is exemplary; on the balance sheet it has been passive to a fault for two decades.

M&A — disciplined to the point of austerity. In ~25 years Veeva has made only two acquisitions of note: Crossix (data/analytics, ~$430M, 2019) and Ostro (Rise Healthcare Tech — AI patient/HCP engagement, ~$100M cash plus retention equity, closed ~Mar-2026). Goodwill has sat flat at $439.9M for 5+ years with zero impairments ever — the antithesis of the serial-acquirer goodwill-writedown pattern seen elsewhere. The real capital allocation is R&D at ~24% of revenue ($767M in FY26): Veeva builds rather than buys, and the build has produced the entire Vault franchise. This is a genuine strength and a major reason the moat compounds.

The cash hoard — the central blemish. ~$6.5B of cash and investments, zero debt, ~$1.4B/yr of FCF, trivial capex — and, for almost the entire public history, no dividend and no buyback. Excess cash earned T-bill yields while the business needed essentially none of it. This is a real drag on ROE/ROIC and lazy stewardship of excess capital. Management’s stated rationale is conservatism and M&A optionality, but the M&A has been so sparing that the optionality argument is weak.

The first-ever buyback — right idea, poor first execution. On January 5, 2026 the board authorized a $2.0B repurchase — the first in company history. Veeva bought 801,735 shares at $224.43 (~$180M) in January 2026, leaving ~$1.82B undeployed. That first tranche is deeply underwater versus the ~$153 current price — clumsy timing into what proved to be a local high. The redeeming feature: the bulk (~$1.82B) is undeployed and could be bought far cheaper now; whether management does buy aggressively into the ~50% drawdown is a live test of capital-allocation credibility (and, so far, they have chosen the buyback over open-market insider purchases).

Stock-based compensation as capital allocation. SBC of $472.7M (14.8% of revenue, trending down from 16.7%) drives ~1.5%/yr net dilution — modest for growth-SaaS, and now partly offsettable by the buyback authorization.

Governance and incentive alignment — the second blemish. Two facts overturn common assumptions and one is a genuine red flag:

• No dual-class / no super-voting (assumption overturned). The IPO-era Class A/B (10x) structure sunset with the Feb-2021 PBC conversion. Veeva is now single-class, one-share-one-vote. Founder-CEO Peter Gassner owns ~15.64M shares ≈ 9.4% of shares and 9.4% of votes (identical). The largest outside holder, BlackRock, is ~5%. This is ordinary aligned-founder influence, not entrenchment — shareholders genuinely hold the votes.
• Compensation tied to no financial metric (red flag). Executive comp is explicitly linked “to no company financial performance measure other than our stock price.” There is no ROIC, revenue, billings, margin, or TSR hurdle. Gassner takes a flat ~$471K salary, no cash bonus, and his only equity is a June-2024 grant of 2.65M premium-priced options ($172M grant-date fair value, ~$34M/yr amortized FY26–30), struck at the then-52-week high, with a 60-consecutive-day price hurdle and a 2-year post-exercise hold, and nothing else until ~2030. The structure is unusually long-term and founder-aligned (he eats his own cooking, and the strike was above market), but the absence of any operating-performance metric is a real governance weakness.
• A real say-on-pay rebuke. The 2025 vote was a shareholder rebuke — director support of ~60% (Wallach), ~62% (Ritter), ~81% (Carges) — likely reflecting the $172M grant and the idle cash. The board responded: it authorized the $2B buyback and moved say-on-pay to annual (from triennial). That responsiveness — only possible because there is no super-voting class — is a mild governance positive.

Verdict. Mixed, tilting positive. Management has built and protected business value superbly (organic R&D, near-zero failed M&A, no impairments, contained dilution) but squandered the excess balance sheet for two decades and, when it finally pivoted to returning capital, executed the first tranche poorly. Incentive design is a genuine weak spot (no financial metric), partly mitigated by an unusually long-dated, premium-struck, founder-aligned equity grant and by the single-class structure that lets shareholders actually exert pressure (and they have). The capital-allocation story is improving but unproven on execution.

8. Changes and Headwinds — Last Two Years

The Salesforce divorce and Vault CRM migration (the defining change). The Salesforce OEM agreement expired September 1, 2025, beginning a wind-down to 2030 and forcing Veeva’s CRM base to re-platform onto Vault CRM. This is the single largest strategic change and the source of the stock’s break. On the November-20-2025 (Q3 FY26) call, management cut the implied top-20 retention scorecard from “18 of 20” toward “14 of 20”; by the Q1 FY27 call (Jun-2026) it was “10 Veeva / 6 Salesforce / 4 undecided.” Salesforce Life Sciences Cloud — armed with IQVIA’s licensed CRM IP — is now a confirmed, winning competitor for a meaningful minority of the largest accounts.

The AI pivot — Veeva Falcon and Ostro. At the May-2026 Veeva Summit the company launched Veeva Falcon, an “agentic labor” platform automating outsourced clinical-document, safety-case, and regulatory work on a per-task/per-document (consumption) basis — reporting directly to the CEO, with a late-2026 commercial ramp. It also closed Ostro (AI engagement, ~$100M) in early 2026. The framing is additive (capturing services budgets) rather than seat-cannibalizing — Veeva’s answer to the “AI kills SaaS seats” narrative. Monetization is immaterial in FY27 guidance; it is optionality.

Solution-area reporting change. Veeva re-cut its segments from “Commercial Cloud / Development Cloud” to “Commercial Solutions / R&D and Quality Solutions” (FY2025), improving visibility into the CRM-vs-Vault divergence that now dominates the thesis.

Capital-return inflection. The first-ever buyback ($2.0B authorized Jan-2026) and the move to annual say-on-pay mark a governance/capital-allocation shift in response to the 2025 say-on-pay rebuke.

Headwinds. (1) The CRM contest above. (2) A broad 2026 application-SaaS / AI-disruption de-rate crushing Veeva’s factor-neighbors (DOCU, HUBS, PCOR). (3) Growth deceleration from 25–30% to ~16% and the durability question that creates. (4) End-market cyclicality — biotech funding and IRA/drug-pricing pressure on pharma R&D budgets. (5) Rate-sensitive interest income (~9% of pretax income) if rates fall.

Verdict. On balance these clarify rather than weaken the long-term thesis but explain the near-term pain. The Salesforce migration genuinely narrowed the Commercial moat (a real negative); the AI pivot and capital-return inflection are net positives still to be proven; the de-rate is largely sentiment. The thesis is intact where it matters (R&D/Quality) and contested where the market is now over-focused (CRM).

9. Risk Analysis (Risk Matrix)

Reading the matrix. The risk profile is asymmetric: the high-impact risks (CRM loss, growth deceleration, end-market downturn) are real and medium-likelihood, but the catastrophic risks are remote (net cash, no debt, mission-critical recurring software). The dominant risk is not ruin but dead money — the multiple staying at trough while a contested-CRM/decelerating-growth narrative persists. The dominant opportunity is the mirror: that the high-impact risks prove overstated for the ~55% majority.

10. Valuation Discussion (Embedded Expectations)

Setup. At $153.30 (Jun-18-2026), market cap is ~$25.15B; net cash of ~$6.5B (~$39/share) gives an enterprise value of ~$18.7B. All multiples below are EV-based unless noted.

Current multiples and the own-history de-rate.

The own-history de-rate is real, not a data artifact. ROIC.ai’s multiple series corroborates the AZI 2nd-percentile flag: EV/Sales ran ~27x at the FY21 bubble, ~8.4x at the Jan-2026 fiscal close (stock ~$204), and ~5.8x live at $153 — below the within-FY26 low, because the worst of the crash is post-fiscal-year (the Apr-2026 trough). This is the cheapest VEEV has ever traded on every standard metric.

Cross-sectionally, though, it is mid-priced, not the cohort bargain. VEEV’s ~5.8x EV/sales sits between premium peers (ServiceNow ~7.7x) and the cheap incumbents (Salesforce/Workday/Adobe ~3–4x), and its ~19.6x forward P/E is a premium to busted incumbents. The signal is therefore own-history >> cross-sectional: VEEV is cheap relative to itself (a quality compounder that lost its entire growth premium), not cheap relative to the de-rated software universe. A buyer is paying a quality premium to the cohort for a regulated monopoly with net cash and 44% margins.

Embedded-expectations / reverse-DCF. At ~$18.65B EV on ~$1.5B FCF and a ~9% WACC, the market is pricing only ~3–5% perpetual FCF growth — i.e., Veeva as a maturing utility. For perspective, flat $1.5B FCF capitalized at 9%/3% already implies >$25B of value versus the $18.65B EV — so the current price embeds either modest decline or a meaningful tail-risk discount. Against a business that compounded FCF ~21%/yr over FY21–26 and is guiding ~16% near-term, the gap between ~16% delivered and ~3–5% embedded is the entire bull case.

Scenario analysis (3-year; EV/share ranges — scenario framing, not a price target).

The skew is asymmetric and up-tilted. The downside is shallow — net cash (~$39/share), 44% FCF margins, and a 7.6% EV/FCF yield establish a floor at roughly dead-money, not collapse; even the bear case is near the current price, not far below it. The upside requires only that the CRM/AI fear prove overdone, which the +20% R&D/Quality majority is already partly disproving. The catch, captured by the factor read: the timing is uncertain — this is a falling knife that has not stabilized, so the path to the base/bull case may include further downside or an extended period of dead money before the re-rate.

What the market is pricing correctly vs incorrectly. Correctly: that CRM is genuinely contested (Salesforce is winning some top-20 accounts), that growth has durably stepped down from 25–30%, and that the bubble-era premium is gone for good. Plausibly incorrectly: that a ~45%-revenue CRM problem and a generic “AI kills SaaS” narrative justify pricing the entire company — including the dominant, accelerating, AI-insulated ~55% regulated Vault franchise — as a no-growth utility.

11. Variant Perception

Consensus belief. “Veeva is a high-quality, mission-critical life-sciences-software monopoly — but its CRM franchise is now structurally contested by Salesforce, growth has durably decelerated to the mid-teens, AI threatens application-SaaS broadly, and the stock — while cheap versus its own bubble-era multiples — is dead money until the CRM and AI questions resolve.” The tape agrees: down ~46% in twelve months, no momentum turn.

Strongest bull case. The ~50% de-rate over-extrapolated a ~45%-of-revenue CRM contest onto a business whose ~55% majority (R&D/Quality) is accelerating, near-uncontested, AI-insulated (document/consumption-centric, not seat-based), and built on regulatory switching costs and proprietary data that no AI competitor can easily replicate. At a 2nd-percentile-ever multiple, ~7.6% FCF yield, ~16% growth, 44% margins, net cash, and >100% return on operating capital, the market is pricing ~3–5% perpetual growth for a business doing ~16% — an asymmetric, downside-floored setup where the CRM/AI fear need only be overdone, not wrong.

Strongest bear case. CRM is being structurally lost — the scorecard genuinely deteriorated (18/20 → 14/20 → “10 Veeva/6 Salesforce/4 undecided”), Salesforce now has IQVIA’s CRM IP, and that’s ~45% of revenue eroding. AI is a systemic threat to seat-based software that will eventually compress both segments, not just Commercial. Growth keeps decelerating, the company is a single-vertical bet exposed to IRA/biotech-funding shocks, capital allocation just proved fallible (buyback at $224), comp is tied to no operating metric, and “2nd-percentile vs its own bubble” is a low bar — 27x trailing / 19.6x forward GAAP P/E is not objectively cheap. “Cheap” can stay cheap: a value trap.

The 3–5 assumptions that matter most, with falsification tests:

1. CRM scorecard trajectory. Bull needs: the win/loss scorecard to stabilize or improve over the next 2–4 quarters. Falsified if: Salesforce wins the majority of remaining top-20 re-platforming decisions (scorecard slips below ~10 Veeva).
2. AI is consumption-additive, not seat-destructive. Bull needs: Falcon/Veeva AI to monetize as incremental (services-budget capture). Falsified if: AI demonstrably compresses CRM seat counts or pricing, or R&D/Quality renewals soften on AI substitution.
3. R&D/Quality durability. Bull needs: the ~55% Vault majority to hold ~20% growth. Falsified if: R&D/Quality decelerates below ~15%, proving the problem is system-wide, not CRM-contained.
4. Multiple normalization vs permanent de-rating. Bull needs: some re-rating as durability is proven. Falsified if: the multiple stays sub-6x EV/sales through 2+ years of ~16% growth (the premium is permanently gone).
5. Terminal-margin durability. Bull needs: 44%+ non-GAAP / high-20s GAAP margins to hold. Falsified if: the CRM re-platforming and AWS/Salesforce double-cost overlap durably compress subscription margins beyond the transient wind-down headwind.

Factor-positioning read (from the momentum/factor workstream). VEEV is a low-beta (0.76), highly idiosyncratic (R² 0.32, ~30% specific vol), falling knife that has not yet stabilized — down ~46% over twelve months, ~55% off its peak, ~1% off its 52-week low, no momentum turn, sitting squarely in the busted-application-SaaS factor bucket (DOCU/HUBS/PCOR). The factor evidence supports a contrarian-value / quality-at-a-trough-multiple framing, not a momentum one — and explicitly warns that a value buyer here is early by the tape: net cash and margins cap the downside, but the absence of any momentum or insider-buying confirmation caps near-term timing confidence. The variant perception is thus a bet that fundamentals (the AI-insulated R&D/Quality majority) will reassert against a sentiment-driven price, on an uncertain timeline.

12. Fact vs. Interpretation Table

13. Open Questions

1. CRM scorecard direction: Does the top-20 win/loss stabilize/improve, or does Salesforce keep taking share through the 2030 wind-down? (The single most important swing variable.)
2. At-risk CRM revenue: Management has refused to size the revenue at risk from the ~6 of 20 leaning to Salesforce. What is the actual $ exposure, and how much is offset by mid-market/biotech Vault CRM wins (Teva, Merck KGaA cited)?
3. AI monetization: Will Falcon/Veeva AI monetize as consumption-additive at scale, and when does it become a reportable number (immaterial in FY27)?
4. R&D/Quality durability: Can the ~55% Vault majority sustain ~20% as it scales, or does it converge toward the blended mid-teens?
5. Buyback execution: Will management deploy the ~$1.82B remaining authorization aggressively into the drawdown (a credibility test), or sit on cash again?
6. Subscription-margin trajectory: How large and how transient is the Salesforce-royalty + AWS double-cost overlap headwind through the 2030 migration?
7. End-market: How exposed is new-logo growth to the biotech funding cycle and IRA-driven pharma R&D budget pressure?

14. What Must Be True

Bull case — what must be true: The dominant ~55% R&D/Quality franchise sustains ~20% growth and remains AI-insulated; the Commercial-CRM contest stabilizes (Veeva retains a solid majority of its base even if Salesforce takes a minority of top-20 accounts); AI proves consumption-additive (Falcon monetizes) rather than seat-destructive; and the market eventually re-rates a ~16%-growing, 44%-margin, net-cash regulated monopoly above its current ~3–5%-perpetual-growth-implied multiple.

Falsification test: R&D/Quality growth decelerates below ~15%, OR the CRM scorecard slips below ~10-of-20 (Salesforce winning the majority), OR two-plus years of ~16% growth pass with the multiple still sub-6x EV/sales. Any one breaks the bull thesis.

Bear case — what must be true: CRM is structurally lost to Salesforce (an accelerating, not stabilizing, scorecard decline); AI is a systemic seat-and-pricing threat that eventually compresses both segments; growth keeps decelerating toward the high single digits; and the single-vertical exposure delivers an IRA/biotech-funding shock — such that 27x trailing / 19.6x forward earnings proves expensive, not cheap, and the stock is a value trap.

Falsification test: The CRM win/loss scorecard stabilizes or improves over 2–4 quarters, R&D/Quality holds ~20%, and Falcon/Veeva AI posts evidence of incremental monetization. Any of these undermines the bear thesis.

15. Source Appendix

The full enumerated source list with URLs and access dates appears in Appendix B below. Primary sources relied upon:

• Veeva Systems FY2026 Form 10-K (year ended Jan-31-2026; filed 2026-03-20), SEC EDGAR, CIK 0001393052 — revenue, segments, margins, Salesforce agreement terms, balance sheet.
• Veeva Q1 FY2027 Form 10-Q (quarter ended Apr-30-2026; filed 2026-06-05) — Q1 results, buyback status.
• Veeva DEF 14A (most recent) — compensation structure, Gassner ownership, single-class structure, say-on-pay results.
• Veeva 8-K filings (Jan-2026 buyback authorization; quarterly earnings) — material events timeline.
• Form 4 corpus (trailing 60 months) — insider transaction read.
• Veeva earnings-call transcripts — Q3 FY2026 (Nov-20-2025), Q4/FY2026, Q1 FY2027 (Jun-3-2026) — via ROIC.ai — CRM scorecard, Falcon AI, guidance.
• AZI valuation_index and price series (accessed 2026-06-19) — own-history valuation percentiles, 5-year price arc.
• FactorsToday factor model (accessed 2026-06-19) — beta, factor loadings, relative strength, risk-adjusted track record, factor-similar peers.
• ROIC.ai — multi-year statements, ratios, enterprise value, valuation-multiple history.

Management commentary throughout is treated as hypothesis, validated against filings and financials. Facts are cited; interpretations and assumptions are labeled. This memo contains no investment recommendation and no price target outside the clearly-labeled Claude’s Take block.

APPENDIX A — Standard Diligence Questionnaire — Veeva Systems Inc. (NYSE: VEEV)

Supplemental to the research memo. Report date 2026-06-19. Fact/Interpretation/Assumption labels applied where material.

General

What thoughtful questions have other investors asked about this company? The dominant question since Nov-2025 is whether the Salesforce→Vault CRM migration is a moat-deepening full-stack consolidation or the moment Salesforce (now armed with IQVIA’s CRM IP) permanently takes the ~45%-revenue Commercial franchise. Secondary: (a) is the ~16% growth a durable plateau or a slope toward maturity; (b) is AI a threat (seat compression) or an opportunity (Falcon consumption revenue); © why hoard $6.5B and only now (clumsily) buy back stock; (d) is a 27x trailing P/E “cheap” simply because it is the lowest in the company’s history. Michael Burry’s Scion was flagged in the news feed as a contrarian dip-buyer (verify via 13F). (Interpretation, from transcripts + news feed.)

Cyclicality & Earnings Nature

Cyclical high or low? Neither extreme; margins are near a structural high (28.7% GAAP op margin, up from an 18% FY24 trough) while growth and valuation are at a cyclical/sentiment low. External vs internal? The de-rate is largely external (sector AI-SaaS re-rate) plus one internal disclosure (CRM scorecard). Earnings power itself is internally driven and resilient. Revenue stability: very high — 84% subscription, ~95% recurring, multi-year contracts, deferred-revenue float, CFO/NI 1.56–1.79x. Outlook: R&D/Quality ~20%, Commercial ~11–14%, blended ~16%; AI/Falcon optionality on top. Market size: large and growing — life-sciences R&D + commercial software/data digitization, a multi-decade tailwind; management aspires to $20B+ revenue long-term. Domestic ~60% / international ~40%.

Business Quality & Competitive Moat

Industry more or less competitive? More competitive in Commercial CRM (Salesforce re-entry); stable-to-consolidating in R&D/Quality (legacy Oracle/Medidata/OpenText retreating; IQVIA exited CRM). Profitability: elite — 75.5% gross margin, 23% ROE, >100% return on operating capital ex-cash, negative tangible invested capital. The headline ~10.5% ROIC is depressed by the idle $6.5B cash; it understates economics (Interpretation). Industry profitability / barriers: few competitors per workflow; barriers = regulatory validation (GxP/21 CFR Part 11), narrow-vertical scale economics, proprietary data. Understandable? Yes — vertical SaaS + data. Undermined by low-cost foreign labor? No — regulated, embedded, mission-critical software. Do brands matter? Veeva is the de facto standard in several life-sciences workflows — reputational/standard-setting value, less consumer-brand. Nature of competition: workflow-by-workflow vs legacy/in-house (R&D/Quality) and vs Salesforce LSC (Commercial). Switching costs: very high in regulated R&D/Quality (re-validation risk); temporarily lowered during the forced CRM re-platforming — the central risk.

Financial Condition & Balance Sheet

Assets not on the balance sheet? The validated installed base / regulatory embeddedness and proprietary data (OpenData/Crossix) are worth far more than booked goodwill ($439.9M). Off-balance-sheet liabilities? None material; only ~$96M finance leases. Accounting conservatism: conservative — deferred revenue grows in line with revenue (no pull-forward), goodwill flat 5+ yrs, zero impairments ever, CFO > NI consistently. Caveat: non-GAAP op margin (44.9%) is ~92% SBC add-back; true owner margins are nearer GAAP 28.7% (Interpretation). CapEx-hungry? No — asset-light, near-zero capex, ~44% FCF margin.

Capital Allocation & Management

FCF and its use: ~$1.4B/yr FCF; for ~25 years used for nothing (no dividend, no buyback) — hoarded as cash earning T-bills. Pivoted Jan-2026 to a first-ever $2.0B buyback, of which $180M was bought at $224.43 (now underwater); ~$1.82B undeployed. Philosophy: superb operator (organic R&D ~24% of revenue), austere acquirer, passive treasurer. Recent acquisitions: only two of note ever — Crossix (~$430M, 2019), Ostro (~$100M, 2026, AI). Buying back shares? Yes, newly and so far poorly timed. Issuing shares to insiders? SBC 14.8% of revenue (falling); net dilution ~0.7–1.5%/yr — modest. Director/management comp: tied to no financial metric other than stock price (red flag); Gassner ~$471K salary + $172M premium-struck options (2024, to ~2030); 2025 say-on-pay rebuke prompted the buyback + annual say-on-pay. Motivations: founder-CEO Gassner owns 9.4% (single-class, no super-voting), long-dated equity above market — long-term aligned, but with weak performance-metric design.

Valuation & Market Data

ADR/MLP/K-1? No — ordinary single-class U.S. common stock (NYSE), 1099 reporting. Dividend policy: none (no dividend ever). Profitability: see above — elite. Net income vs CFO divergence: CFO consistently exceeds net income (1.56–1.79x) — earnings are cash-backed, a positive. Valuation: EV ~$18.7B; EV/Rev ~5.8x, EV/FCF ~13x, fwd P/E ~19.6x (net-cash-adjusted ~20.3x trailing); 2nd-percentile of own 10-yr history on P/E/P/S/P/B; cross-sectionally mid-priced (quality premium to busted-SaaS peers).

Risks & Downside

What would cause the stock to decline (further)? Continued CRM scorecard deterioration; R&D/Quality deceleration; AI proving seat-destructive system-wide; a biotech-funding/IRA pharma-budget shock; another mistimed capital deployment; the multiple staying at trough (value trap). Catastrophic loss risk? Low — net cash, no debt, 44% FCF margin, mission-critical recurring software. Total loss? Very low — durable cash-generative franchise; the realistic adverse case is dead money, not impairment of capital.

Recent News & Events

Has the environment changed recently? Yes, materially: the Salesforce OEM agreement expired (Sep-2025) and the Nov-2025 disclosure of a softer top-20 CRM retention scorecard triggered the break; the broad 2026 AI-SaaS de-rate amplified it. Acquisitions: Ostro (AI, ~2026). Accounting changes: segment reporting re-cut to Commercial Solutions / R&D & Quality Solutions (FY2025) — improved visibility. Other recent changes: Veeva Falcon agentic-AI platform launched (May-2026, late-2026 ramp); first-ever $2B buyback (Jan-2026); move to annual say-on-pay; new global Vault CRM wins cited (Teva, Merck KGaA).

APPENDIX B — Source Appendix — Veeva Systems Inc. (NYSE: VEEV)

Report date 2026-06-19. Primary sources prioritized over secondary. All figures reconciled to SEC filings where the issuer is a US filer (CIK 0001393052). Management commentary treated as hypothesis and validated against filings/financials.

Primary — SEC Filings (EDGAR, CIK 0001393052)

1. Form 10-K, FY2026 (fiscal year ended Jan-31-2026; filed 2026-03-20). Revenue $3,195.3M; subscription $2,684.2M; Commercial Solutions $1,446.9M / R&D & Quality Solutions $1,748.4M; gross margin 75.5%; GAAP op margin 28.7%; Salesforce OEM agreement expiry (Sep-1-2025) and wind-down terms (to 2030; Veeva CRM support to Dec-31-2029); $6.5B cash/investments; goodwill $439.9M. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001393052
2. Form 10-Q, Q1 FY2027 (quarter ended Apr-30-2026; filed 2026-06-05). Revenue $882.9M (+16.3%); op margin 30.9%; buyback status (~$1.82B remaining).
3. Form 10-K, FY2025 / FY2024 / FY2023 / FY2022 — multi-year revenue, margin, SBC, share-count trends (corpus mirrored to output/VEEV/sources/10-K/).
4. DEF 14A (latest) + DEFA14A — executive compensation (no financial metric; Gassner $471K salary + $172M premium-struck 2024 options); single-class structure (post-Feb-2021 PBC conversion); Gassner ownership ~15.64M shares ≈ 9.4%; 2025 say-on-pay results (director support ~60–81%); move to annual say-on-pay.
5. Form 8-K, Jan-5-2026 — $2.0B share-repurchase authorization (first in company history).
6. Form 8-K (quarterly earnings) — Q3 FY2026 (~Nov-2025), Q4/FY2026, Q1 FY2027 — material-events timeline.
7. Form 4 corpus (trailing 60 months; 505 filings listed in MANIFEST.csv) — insider transactions: zero open-market purchases (code P) through the ~50% drawdown; Gassner zero sells since the June-2024 grant; immaterial 10b5-1 director sells (Hung, Schwenger).

Primary — Earnings-Call Transcripts (via ROIC.ai)

8. Q3 FY2026 call (Nov-20-2025) — top-20 CRM retention scorecard cut from “18 of 20” toward “14 or so”; Q3 beat + raised full-year guide; the −9.8% next-day move. Saved to output/VEEV/transcripts/.
9. Q4/FY2026 call — FY26 rev $3.195B; non-GAAP op income $1.434B; CRM ~20% of revenue (was ~25% two years prior); Salesforce-royalty + AWS double-cost subscription-margin headwind through ~2030.
10. Q1 FY2027 call (Jun-3-2026) — rev $883M, ~44.7% non-GAAP op margin; CRM scorecard “10 Veeva / 6 Salesforce / 4 undecided”; Veeva Falcon agentic-AI platform; Ostro (~$10M FY27 contribution); new global Vault CRM wins (Teva, Merck KGaA).

Primary — Market & Quantitative Data

11. AZI price series (download-data.php?t=VEEV; accessed 2026-06-19) — 5-year OHLCV, EMAs, beta. ATH $341.00 (2021-08-05); 52wk high $306.22 (2025-10-07); 52wk low $151.43 (2026-04-10); close $153.30 (2026-06-18); 200-EMA ~$202.
12. AZI valuation_index (fundamentals; accessed 2026-06-19) — own-history percentiles: P/E 27.24x (2nd pctile), P/B 3.48x (2nd pctile), P/S 7.73x (2nd pctile), composite 2nd pctile; TTM EPS $5.63, BVPS $44.0, sales/share $19.84.
13. FactorsToday (accessed 2026-06-19) — /stock-info: beta 0.76, alpha −0.22, rs_peak −55.04%, rs_12m −45.62%, rs_6m −30.1%; /leaderboard: y10 +16.2%/yr, y5 −12.8%/yr, y1 −45.5%; /stock-specific-vol: 30.1%, R² 0.32; /stock-loadings: Market 0.76–0.84, Industry:Cloud Computing 0.40–0.53; /related-stocks: DOCU, HUBS, PCOR, NABL, PD, FRSH.
14. ROIC.ai (accessed 2026-06-19) — multi-year income statement / balance sheet / cash flow; profitability ratios; enterprise value (~$18.65B); valuation-multiple history (EV/Sales 27x FY21 → 8.4x Jan-2026 → ~5.8x live); per-share data.

Secondary / Comparative

16. AZI news feed (scripts/azi.sh news VEEV; accessed 2026-06-19) — May–Jun 2026 window; aggregate scored sentiment positive (Falcon launch, Teva/Merck KGaA wins, Q1 beat); Scion/Burry contrarian-buyer mentions (to verify via 13F).

Notes on data quality / reconciliation

• ROIC.ai and AZI figures are third-party aggregated data; for US-filer figures the 10-K/10-Q are primary and authoritative — material numbers were reconciled to filings.
• Non-GAAP operating margin (~44.9%) is management-defined; the ~16-pt gap to GAAP (28.7%) is ~92% stock-based compensation — a real, dilutive (if non-cash) cost.
• Headline ROIC (~10.5%) is depressed by ~$6.5B idle cash in the denominator; the memo uses a return-on-operating-capital-ex-cash measure (~107%) as the truer economic figure (Interpretation, derived from filings).
• The AZI news feed window did not reach the Nov-2025 crash; the crash driver was sourced from the Q3 FY2026 transcript and 8-K and the price series.